Efficacy and safety of laser-assisted combination chemotherapy: A follow-up study of treatment with 5-fluorouracil and cisplatin for basal cell carcinoma.
5-Fluourouracil
ablative fractional CO2 laser
cisplatin
laser-assisted drug delivery
optical coherence tomography
skin cancer
topical chemotherapy
topical drug delivery
Journal
Lasers in surgery and medicine
ISSN: 1096-9101
Titre abrégé: Lasers Surg Med
Pays: United States
ID NLM: 8007168
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
10
11
2021
received:
02
09
2021
accepted:
12
11
2021
pubmed:
6
12
2021
medline:
28
1
2022
entrez:
5
12
2021
Statut:
ppublish
Résumé
There is a growing need for effective topical treatments for basal cell carcinoma (BCC). By altering the skin barrier, ablative fractional lasers (AFLs) enhance cutaneous uptake of the synergistic chemotherapeutic agents, cisplatin, and 5-fluorouracil (5-FU). In our recently reported clinical trial, AFL-assisted delivery of cisplatin and 5-FU showed favorable short-term clearance rates of 95% with good cosmetic results at 3 months. This follow-up study assessed sustained tumor clearance, safety, and cosmesis in the same patient cohort, observed 6- and 12-months posttreatment. This follow-up study assessed AFL-assisted cisplatin and 5-FU in low-risk BCC. Among the 18/19 patients who achieved clinical tumor clearance in our 3-months primary trial, all were included for a 6-months follow-up. At 12 months, 17/19 were included due to one 6-month residual. During follow-up visits, treated areas were evaluated for signs of recurrent tumour by clinical inspection and optical coherence tomography (OCT). Residual tumors were confirmed histologically. Cosmetic outcome was evaluated at both follow-up visits by patients and physicians. Overall, complete tumor clearance was 89% (17/19) and 79% (15/19) at 6 and 12 months, respectively. Clearance rate for superficial BCCs (sBCCs) 1 year after treatment was 100% (6/6) and lower for nodular BCC (nBCC) at 69% (9/13). Among recurrent tumors, 67% (2/3) had received only a single treatment and all were of the nodular subtype, situated in the head and neck area. All histologically confirmed BCC recurrences were identified by OCT. Cosmetic outcomes were similarly rated "good" or "excellent" by patients and evaluators (p = 0.289 and p = 0.250). Treatment-related local skin reactions were mild and tolerable, consisting of persisting erythema in two patients at the end of the study. Dyspigmentation was commonly observed at both follow-up visits, while the appearance of scarring resolved in the majority of patients between 6 months (56%; 10/18) and 12 months (76%; 13/17). AFL-assisted cisplatin + 5-FU in double sessions represents an acceptable and safe treatment strategy for low-risk sBCC, while clearance rates following single treatment or for nBCC seem inferior. This intensified topical strategy may be best suited to cases of multiple lesions or in instances where surgical excision or extended courses of at-home therapy is challenging.
Sections du résumé
BACKGROUND AND OBJECTIVES
There is a growing need for effective topical treatments for basal cell carcinoma (BCC). By altering the skin barrier, ablative fractional lasers (AFLs) enhance cutaneous uptake of the synergistic chemotherapeutic agents, cisplatin, and 5-fluorouracil (5-FU). In our recently reported clinical trial, AFL-assisted delivery of cisplatin and 5-FU showed favorable short-term clearance rates of 95% with good cosmetic results at 3 months. This follow-up study assessed sustained tumor clearance, safety, and cosmesis in the same patient cohort, observed 6- and 12-months posttreatment.
MATERIALS AND METHODS
This follow-up study assessed AFL-assisted cisplatin and 5-FU in low-risk BCC. Among the 18/19 patients who achieved clinical tumor clearance in our 3-months primary trial, all were included for a 6-months follow-up. At 12 months, 17/19 were included due to one 6-month residual. During follow-up visits, treated areas were evaluated for signs of recurrent tumour by clinical inspection and optical coherence tomography (OCT). Residual tumors were confirmed histologically. Cosmetic outcome was evaluated at both follow-up visits by patients and physicians.
RESULTS
Overall, complete tumor clearance was 89% (17/19) and 79% (15/19) at 6 and 12 months, respectively. Clearance rate for superficial BCCs (sBCCs) 1 year after treatment was 100% (6/6) and lower for nodular BCC (nBCC) at 69% (9/13). Among recurrent tumors, 67% (2/3) had received only a single treatment and all were of the nodular subtype, situated in the head and neck area. All histologically confirmed BCC recurrences were identified by OCT. Cosmetic outcomes were similarly rated "good" or "excellent" by patients and evaluators (p = 0.289 and p = 0.250). Treatment-related local skin reactions were mild and tolerable, consisting of persisting erythema in two patients at the end of the study. Dyspigmentation was commonly observed at both follow-up visits, while the appearance of scarring resolved in the majority of patients between 6 months (56%; 10/18) and 12 months (76%; 13/17).
CONCLUSION
AFL-assisted cisplatin + 5-FU in double sessions represents an acceptable and safe treatment strategy for low-risk sBCC, while clearance rates following single treatment or for nBCC seem inferior. This intensified topical strategy may be best suited to cases of multiple lesions or in instances where surgical excision or extended courses of at-home therapy is challenging.
Substances chimiques
Cisplatin
Q20Q21Q62J
Fluorouracil
U3P01618RT
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-120Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069-80.
Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327(7418):794-8.
Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007;1:CD003412.
Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007;4(8):462-9.
Jansen MHE, Mosterd K, Arits AHMM, Roozeboom MH, Sommer A, Essers B, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol. 2018;138(3):527-33.
Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647-54.
Arits, AHMM, Spoorenberg, E, Mosterd, K, et al. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma. Br J Dermatol. 2014;171(6):1501-07.
Mohs FE, Jones DL, Bloom RF. Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol. 1978;114(7):1021-22.
Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol. 1981;4(6):633-49.
McGillis ST, Fein H. Topical treatment strategies for non-melanoma skin cancer and precursor lesions. Semin Cutan Med Surg. 2004;23(3):174-83.
Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. Dermatologica. 1979;158(5):368-72.
Wenande E, Anderson RR, Haedersdal M. Fundamentals of fractional laser-assisted drug delivery: an in-depth guide to experimental methodology and data interpretation. Adv Drug Deliv Rev. 2020;153:169-84.
Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis-a systematic review of randomized controlled trials. Int J Dermatol. 2009;48(5):453-63.
Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer. 1985;56(12):2740-44.
Wenande E, Olesen UH, Nielsen MM, Janfelt C, Hansen SH, Anderson RR, et al. Fractional laser-assisted topical delivery leads to enhanced, accelerated and deeper cutaneous 5-fluorouracil uptake. Expert Opin Drug Deliv. 2017;14(3):307-17.
Chabner BA, Longo DL. Cancer chemotherapy and biotherapy: principles and practice. 5. ed. Wolters Kluwer Health; 2015.
Swinnen LJ, Fisher SG, Erickson LC. Ultraviolet irradiation produces cytotoxic synergy and increased DNA interstrand crosslinking with cis- and trans-diamminedichloroplatinum(II). Carcinogenesis. 1989;10(8):1465-70.
Roberts JJ, Thomson AJ. The mechanism of action of antitumor platinum compounds. Prog Nucleic Acid Res Mol Biol. 1979;22:71-133.
Featherstone J, Dykes PJ, Marks R. The effect of platinum complexes on human skin cells in vivo and in vitro. Skin Pharmacol Off J Skin Pharmacol Soc. 1991;4(3):169-74.
Gil S, Yébenes M, Luelmo J, Alsina M, Sabés M. A comparative study of the effectiveness of cisplatin and 5-fluorouracil on cutaneous squamous human carcinoma cell line: potential chemotherapy alternative to surgery. Dermatol Ther. 2016;29(5):341-4.
Olesen UH, Bojesen S, Gehl J, Haedersdal M. Anticancer drugs and the regulation of Hedgehog genes GLI1 and PTCH1, a comparative study in nonmelanoma skin cancer cell lines. Anticancer Drugs. 2017;28(10):1106-17.
Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma-a review of the literature. Acta Oncol Stockh Swed. 1996;35(6):677-82.
Bejar C, Maubec E. Therapy of advanced squamous cell carcinoma of the skin. Curr Treat Options Oncol. 2014;15(2):302-20.
Trodello C, Pepper JP, Wong M, Wysong A. Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2017;43(1):40-9.
Ghezzi A, Aceto M, Cassino C, Gabano E, Osella D. Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS). J Inorg Biochem. 2004;98(1):73-8.
Simonetti LDD, Gelfuso GM, Barbosa JCR, Lopez RFV. Assessment of the percutaneous penetration of cisplatin: the effect of monoolein and the drug skin penetration pathway. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2009;73(1):90-4.
Bay C, Lerche CM, Ferrick B, Philipsen PA, Togsverd-Bo K, Haedersdal M. Comparison of physical pretreatment regimens to enhance protoporphyrin IX uptake in photodynamic therapy: a randomized clinical trial. JAMA Dermatol. 2017;153(4):270-8.
Wenande E, Phothong W, Bay C, Karmisholt KE, Haedersdal M, Togsverd-Bo K. Efficacy and safety of daylight photodynamic therapy after tailored pretreatment with ablative fractional laser or microdermabrasion: a randomized, side-by-side, single-blind trial in patients with actinic keratosis and large-area field cancerization. Br J Dermatol. 2019;180(4):756-64.
Erlendsson AM, Olesen UH, Haedersdal M, Rossi AM. Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors-clinical review and future perspectives. Adv Drug Deliv Rev. 2020;153:185-94.
Haedersdal M, Erlendsson AM, Paasch U, Anderson RR. Translational medicine in the field of ablative fractional laser (AFXL)-assisted drug delivery: a critical review from basics to current clinical status. J Am Acad Dermatol. 2016;74(5):981-1004.
Karmisholt KE, Taudorf EH, Wulff CB, Wenande E, Philipsen PA, Haedersdal M. Fractional CO2 laser treatment of caesarean section scars-a randomized controlled split-scar trial with long term follow-up assessment. Lasers Surg Med. 2017;49(2):189-97.
Banzhaf CA, Phothong W, Suku MH, Ulrich M, Philipsen PA, Mogensen M, et al. Basal cell carcinoma treated with combined ablative fractional laser and ingenol mebutate-an exploratory study monitored by optical coherence tomography and reflectance confocal microscopy. J Eur Acad Dermatol Venereol JEADV. 2020;34(3):502-9.
Banzhaf CA, Lin LL, Dang N, Freeman M, Haedersdal M, Prow TW. The fractional laser-induced coagulation zone characterized over time by laser scanning confocal microscopy-a proof of concept study. Lasers Surg Med. 2018;50(1):70-7.
Wenande E, Olesen UH, Boesen MR, Persson DP, Lerche CM, Stürup S, et al. Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin. Drug Deliv. 2018;25(1):1877-85.
Wenande E, Tam J, Bhayana B, Schlosser SK, Ishak E, Farinelli WA, et al. Laser-assisted delivery of synergistic combination chemotherapy in in vivo skin. J Control Release Off J Control Release Soc. 2018;275:242-53.
Wenande E, Hendel K, Mogensen M, Bagger C, Mårtensson NL, Persson DP, et al. Efficacy and safety of laser-assisted combination chemotherapy: an explorative imaging-guided treatment with 5-fluorouracil and cisplatin for basal cell carcinoma. Lasers Surg Med. 2021;53(1):119-28.
Haak CS, Togsverd-Bo K, Thaysen-Petersen D, Wulf HC, Paasch U, Anderson RR, et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas-a randomized clinical trial. Br J Dermatol. 2015;172(1):215-22.
Genouw E, Verheire B, Ongenae K, De Schepper S, Creytens D, Verhaeghe E, et al. Laser-assisted photodynamic therapy for superficial basal cell carcinoma and Bowen's disease: a randomized intrapatient comparison between a continuous and a fractional ablative CO2 laser mode. J Eur Acad Dermatol Venereol JEADV. 2018;32(11):1897-905.
Choi SH, Kim KH, Song KH. Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. J Eur Acad Dermatol Venereol JEADV. 2016;30(5):783-8.
Haering N, Boehler C, Barlas K, Dertinger S, Strohal R. The combination of fractionated erbium:YAG laser skin microporation and topical imiquimod is a new, safe and efficient strategy for the treatment of actinic keratosis and basal cell carcinoma: report of two pilot studies. J Dermatol Res Ther. 2015;1(1):7-18.
Hsu SH, Gan SD, Nguyen BT, Konnikov N, Liang CA. Ablative fractional laser-assisted topical fluorouracil for the treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ: a follow-up study. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2016;42(9):1050-53.
Bøgelund FS, Philipsen PA, Gniadecki R. Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol. 2007;87(4):330-4.
Silverman MK, Kopf AW, Grin CM, Bart RS, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. J Dermatol Surg Oncol. 1991;17(9):720-6.
Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol. 1999;135(10):1177-83.
Micali G, Lacarrubba F, Nasca MR, Schwartz RA. Topical pharmacotherapy for skin cancer: part I. Pharmacology. J Am Acad Dermatol. 2014;70(6):965-78.
Olesen UH, Mogensen M, Haedersdal M. Vehicle type affects filling of fractional laser-ablated channels imaged by optical coherence tomography. Lasers Med Sci. 2017;32(3):679-84.
Ibrahim O, Wenande E, Hogan S, Arndt KA, Haedersdal M, Dover JS. Challenges to laser-assisted drug delivery: applying theory to clinical practice. Lasers Surg Med. 2018;50(1):20-7.
Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2007;33(4):433-9.
Ferrante di Ruffano L, Dinnes J, Deeks JJ, Chuchu N, Bayliss SE, Davenport C, et al. Optical coherence tomography for diagnosing skin cancer in adults. Cochrane Database Syst Rev. 2018;12:CD013189.
Cheng HM, Guitera P. Systematic review of optical coherence tomography usage in the diagnosis and management of basal cell carcinoma. Br J Dermatol. 2015;173(6):1371-80.
Sinx KAE, van Loo E, Tonk EHJ, Kelleners-Smeets N, Winnepenninckx V, Nelemans PJ, et al. Optical coherence tomography for noninvasive diagnosis and subtyping of basal cell carcinoma: a prospective cohort study. J Invest Dermatol. 2020;140(10):1962-67.
Hussain AA, Themstrup L, Jemec GBE. Optical coherence tomography in the diagnosis of basal cell carcinoma. Arch Dermatol Res. 2015;307(1):1-10.